Treatment of vascular Parkinson's syndrome after stroke by ultralow frequency and high frequency repetitive transcranial magnetic stimulation.
10.11817/j.issn.1672-7347.2015.04.002
- Author:
Renming XIE
1
;
Yanru LI
;
Da LEI
Author Information
1. Department of Neural Rehabilitation, Xiangya Boai Rehabilitation Hospital, Changsha 410151, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Parkinson Disease;
therapy;
Quality of Life;
Stroke;
complications;
Transcranial Magnetic Stimulation;
Treatment Outcome
- From:
Journal of Central South University(Medical Sciences)
2015;40(4):351-355
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine effect and safety of ultra-low frequency and high frequency repetitive transcranial magnetic stimulation on treating vascular Parkinson's syndrome (VPS) after stroke.
METHODS:The 0.1 Hz low frequency (n=21) and 5 Hz high frequency (n=21) rTMS were used to treat patients with VPS, and the false stimulation servered as a control group (n=18). The UPDRS score and Parkinson's Disease Questionnaire (PDQ) were chosen to evaluate the curative effect on PD. The patients were given anti-PD drugs continuously during the treatment.
RESULTS:UPDRS scores as well as I, II, and III scores after the treatment were significantly decreased in both the ultra-low frequency group and the high frequency group compared with those before the treatment (all P<0.05). The scores at the third month after the treatment were still lower than those before the treatment (P<0.05), but there was no significant difference between the ultra-low frequency and the high frequency group at the same time point before and after the treatment (P>0.05). There was no significant difference in UPDRS scores between before and after the treatment in the control group (P>0.05), but PDQ scores were significantly decreased at the third month after the treatment compared with those of before and after treatment (P<0.05).
CONCLUSION:The low frequency and high frequency repetitive transcranial magnetic stimulation can safely improve the clinical symptoms and life quality of patients with VPS.
